AMGEN and Repatha at ACC

More than 80% of patients pay less than
$50 per month across all payers1,*

Commercial

Eligible commercial patients

may pay $5

with the Repatha® Copay Card

Medicare

~72%

of Repatha® prescriptions

cost less than $501,‡

Medicaid

~100%

of Repatha® prescriptions

cost less than $501

Access for Repatha®

8 out of 10

have formulary coverage for Repatha®2,§

*

Based on IQVIA claims data from 1/1/2020–12/31/2020 using commercial, Medicare, and Medicaid claims.1

Eligibility requirements for Repatha® Copay Card: Open to patients with commercial prescription insurance and who are not enrolled in any government-funded program that pays for prescription drugs. This program is not open to uninsured patients or patients enrolled in any federal-, state-, or government-funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE®, or where prohibited by law. Cash Discount Cards and other noninsurance plans may not be used as primary insurance coverage under this offer. Other restrictions, including annual copay maximum limits, may apply. This offer is subject to change or discontinuation without notice. Please visit Repatha.com for full terms and conditions.

Patient out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit they are currently in. Medicare Part D drug coverage is divided into 4 phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, and 4) Catastrophic.

§

Includes commercial, health exchange, Medicaid, and Medicare lives.2

References: 1. Data on file, Amgen; [1]; 2021. 2. Data on file, Amgen; [2]; 2020.

IMPORTANT SAFETY INFORMATION
  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please click red ^ to view additional Important Safety Information.

Please see full Prescribing Information.